Precision Medicine According to Histologic Subtype in Renal Cell Carcinoma
November 6th 2021During a presentation at the 2021 International Kidney Cancer Symposium, Bradley McGregor, MD, discussed analyses of outcomes based on histology in major RCC clinical trials, and how this approach will shape the future of treatment.
Read More
Treating Post-MPN Acute Leukemia Remains an Unmet Medical Need
October 18th 2021In an interview with Targeted Oncology, Gabriela Hobbs, MD discussed the current treatment landscape for MPNs and the research that is aiming to address post-MPN acute leukemia and unmet needs for the patient population.
Read More
Improving Risk/Benefit of Frontline Classical Hodgkin Lymphoma Treatment
October 17th 2021Many options exist for advanced stage cHL, with varying degrees of toxicity. Ranjana H. Advani, MD, gives an overview of each during a presentation at the NCCN 2021 Virtual Congress: Hematologic Malignancies.
Read More
In Unresectable Stage III NSCLC, Real-World PFS Benefit Reported With PACIFIC Regimen
September 21st 2021Compared with the median PFS reported in the durvalumab arm of the phase 3 PACIFIC trial in patients with stage III non–small cell lung cancer, the median real-world progression-free survival with durvalumab was higher.
Read More
In patients with HER2-positive, metastatic colorectal cancer, fam-trastuzumab deruxtecan-nxki led to improved responses in patients with higher HER2 expression at baseline, whereas responses were seen irrespective of RAS- and PIK3CA mutation status and blood tumor mutational burden levels.
Read More
CASPIAN Update Shows Continued Benefit of Durvalumab/Chemotherapy in ES-SCLC
September 21st 2021In patients with extensive-stage small cell lung cancer, durvalumab added to platinum/etoposide chemotherapy continued to demonstrate an overall survival improvement compared with chemotherapy alone with a favorable safety profile, according to updated data from the phase 3 CASPIAN trial.
Read More
In ER+/HER2– Early Breast Cancer, Giredestrant Induces Greater Ki67 Suppression Vs Anastrozole
September 21st 2021In patients with estrogen receptor–positive, HER2-negative early breast cancer, giredestrant resulted in a greater relative reduction in Ki67 score from baseline to week 2 of a window of opportunity phase vs anastrozole.
Read More
The Rationale Behind Comparing Larotrectinib and Entrectinib In Metastatic Solid Tumors
September 21st 2021Jesús García-Foncillas, MD, PhD, discusses the rationale behind comparing the efficacy of larotrectinib and entrectinib head-to-head in patients with metastatic solid tumors with neurotrophic gene fusions.
Watch
Sitravatinib Plus Nivolumab Induces Durable Responses in Advanced NSCLC After ICIs, Chemotherapy
September 21st 2021Results from the MRTX-500 trial show that sitravatinib administered in combination with nivolumab can elicit durable response and lead to robust survival outcomes for patients with non-small cell lung cancer who progressed after deriving benefit from treatment with a checkpoint inhibitor and/or platinum doublet chemotherapy.
Read More
When comparing de-escalated neoadjuvant ado-trastuzumab emtansine, with or without endocrine therapy, vs trastuzumab plus endocrine therapy baseline tumor immunogenicity may be associated with higher pathologic complete response rates and favorable outcomes in hormone receptor-positive, human epidermal growth factor receptor 2-positive early stage breast cancer.
Read More
Data from the phase 3 CheckMate-649 trial showed that the combination therapy of nivolumab and chemotherapy showed a sustained survival benefit in patients with advanced gastric, gastroesophageal junction (GEJ), or esophageal cancer, in contrast to the combination of nivolumab and ipilimumab.
Read More